MEIP - Wutah pendapatan taun lumaku MEI Pharma Corporation

Logo grafis MEI Pharma Corporation (MEIP)

MEI Pharma, Inc. (MEIP) develops targeted blood cancer therapies leveraging patent-protected molecules and a stable balance sheet. This GURU.Markets chart illustrates the year-over-year revenue change for the TTM, where the indicator level stands at 16.20. Business success is driven by the efficiency of joint research and cash reserves. The company's operations are strictly regulated by the FDA, including rules for the disposal of biomaterials.

Wutah pendapatan YoY sajrone 12 wulan kepungkur: MEI Pharma Inc (MEIP) kanggo 11.02.2024 - 20.02.2024

MEI Pharma (MEIP) - rincian metrik lan laporan keuangan

- kuotasi saiki lan rata-rata prakiraan nilai:
Ringkesan analitik perusahaan:MEIP (MEI Pharma Corporation)
Produk dadi meipharma.com

The year-over-year (TTM) commercial revenue growth trend reflects the commercial success of MEI Pharma, Inc. (MEIP) innovative oncology drugs, recording a current value of 16.20. This indicator measures the percentage change in sales over a rolling 12-month period, allowing investors to promptly assess cash flow resilience to macro shocks and accurately determine the capital entry point prior to the publication of quarterly reports.